Ivermectin and MS

Ivermectin has been identified as a potential candidate to promote remyelination in multiple sclerosis (MS) patients. A study published in EMBO Molecular Medicine found that ivermectin modulates microglia/macrophage inflammatory responses and can promote the repair of myelin damage by activating the purinergic receptor P2X4 (P2X4R) in microglial cells.1 3 6

In an animal model of MS, ivermectin was shown to ease clinical manifestations of experimental autoimmune encephalomyelitis (EAE) and promote remyelination, indicating its potential as a therapeutic agent for MS.6

Further research has shown that ivermectin can protect against EAE in mice by modulating the Th17/Treg balance involved in the IL-2/STAT5 pathway, suggesting its anti-inflammatory effects.2

These findings highlight the potential of ivermectin as a treatment for MS, particularly in promoting the repair of myelin damage and reducing inflammation.